一项全国改良德尔菲共识:优先关注成人重症患者抗精神病药减停的经验与干预措施
该研究采用三轮全国改良德尔菲共识流程,在线调查加拿大57名与ICU患者工作的医生、护士和药师。第1、2轮用9点Likert量表(1=强烈不同意,9=强烈同意)评估抗精神病药处方体验、使用知识与频率、指南推荐知识及减停策略,共识定义为中位评分1-3或7-9。第3轮对达到共识(中位评分7-9)的减停策略陈述用加权排序量表(0-100分)确定优先级。最终优先出6条共识陈述,聚焦限制抗精神病药用于特定患者及优化员工沟通、转诊期沟通工具与药物核对。
要点
- 共识优先推荐将抗精神病药处方限制于高活动性谵妄患者。
- 共识优先推荐将抗精神病药处方限制于因激越对自身、家属和/或员工有风险的患者。
- 共识优先推荐将抗精神病药处方限制于因激越或谵妄影响照护与治疗的患者。
- 共识优先推荐员工间沟通抗精神病药有效性,并采用直接高效的转诊期沟通工具。
- 共识优先推荐在转诊期进行药物核对以促进抗精神病药减停。
适用人群与场景
- 加拿大与ICU患者工作的利益相关者(医生、护士、药师),共57名。
诊断标准与关键阈值
- 共识定义为9点Likert量表(1=强烈不同意,9=强烈同意)中位评分1-3或7-9。
- 第3轮对达到共识(中位评分7-9)的陈述用加权排序量表(0-100分)确定优先级。
处置流程与药物剂量
- 限制抗精神病药处方于高活动性谵妄患者。
- 限制抗精神病药处方于因激越对自身、家属和/或员工有风险的患者。
- 限制抗精神病药处方于因激越或谵妄影响照护与治疗的患者。
- 优先员工间沟通抗精神病药有效性。
- 优先转诊期直接高效的抗精神病药减停沟通工具。
- 优先转诊期药物核对。
研究设计与关键结果
- 研究设计:三轮全国改良德尔菲共识流程,在线调查覆盖加拿大。
- 参与者:57名利益相关者(医生、护士、药师)与ICU患者工作。
- 干预:无。
- 主要结果:优先出6条关于抗精神病药减停策略的共识陈述,聚焦限制处方于高活动性谵妄、因激越对自身/家属/员工有风险、因激越或谵妄影响照护与治疗的患者,以及员工沟通、转诊期沟通工具和药物核对。
证据类型、等级与局限
- 证据类型:全国改良德尔菲共识流程。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为该共识陈述可用于实施干预以促进ICU患者及重症后抗精神病药最小化与减停策略。
指南或共识出处
- Crit Care Explor
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: Antipsychotic medications are frequently prescribed to critically ill patients leading to their continuation at transitions of care thereafter. The aim of this study was to generate evidence-informed consensus statements with key stakeholders on antipsychotic minimization and deprescribing for ICU patients.
DESIGN: We completed three rounds of surveys in a National modified Delphi consensus process. During rounds 1 and 2, participants used a 9-point Likert scale (1-strongly disagree, 9-strongly agree) to rate perceptions related to antipsychotic prescribing (i.e., experiences regarding delivery of patient care), knowledge and frequency of antipsychotic use, knowledge surrounding antipsychotic guideline recommendations, and strategies (i.e., interventions addressing current antipsychotic prescribing practices) for antipsychotic minimization and deprescribing. Consensus was defined as a median score of 1-3 or 7-9. During round 3, participants ranked statements on antipsychotic minimization and deprescribing strategies that achieved consensus (median score 7-9) using a weighted ranking scale (0-100 points) to determine priority.
SETTING: Online surveys distributed across Canada.
SUBJECTS: Fifty-seven stakeholders (physicians, nurses, pharmacists) who work with ICU patients.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Participants prioritized six consensus statements on strategies for consideration when developing and implementing interventions to guide antipsychotic minimization and deprescribing. Statements focused on limiting antipsychotic prescribing to patients: 1) with hyperactive delirium, 2) at risk to themselves, their family, and/or staff due to agitation, and 3) whose care and treatment are being impacted due to agitation or delirium, and prioritizing 4) communication among staff about antipsychotic effectiveness, 5) direct and efficient communication tools on antipsychotic deprescribing at transitions of care, and 6) medication reconciliation at transitions of care.
CONCLUSIONS: We engaged diverse stakeholders to generate evidence-informed consensus statements regarding antipsychotic prescribing perceptions and practices that can be used to implement interventions to promote antipsychotic minimization and deprescribing strategies for ICU patients with and following critical illness.
参考来源
- Jaworska N, Makuk K, Krewulak KD, et al. A National Modified Delphi Consensus Process to Prioritize Experiences and Interventions for Antipsychotic Medication Deprescribing Among Adult Patients With Critical Illness. Crit Care Explor. 2022. PMID: 36506828. doi:10.1097/CCE.0000000000000806
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。